Advances in research and current challenges in the treatment of advanced HER2-low breast cancer
Human epidermal growth factor receptor 2 (HER2)-low breast cancer is defined as breast cancer with an immunohistochemistry (IHC) score of 1+ or 2+ and in situ hybridisation (ISH)-negative. The traditional HER2 classification (negative or positive) has limitations, with only 15%–20% of the breast can...
Tallennettuna:
| Päätekijä: | |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2025-03-01
|
| Sarja: | Frontiers in Cell and Developmental Biology |
| Aiheet: | |
| Linkit: | https://www.frontiersin.org/articles/10.3389/fcell.2025.1451471/full |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|